

# SA-CME Information

## CONTROVERSIES IN LOW DOSE RATE PROSTATE BRACHYTHERAPY

**Description:** Indications for low dose rate prostate brachytherapy (LDR-BT) monotherapy for high-risk or unfavorable intermediate-risk prostate cancer are currently not based on level I evidence. Guidelines discussing brachytherapy indications do not highlight the important RTOG 0232 interim analysis regarding the role of LDR monotherapy and toxicity profile advantage, nor do guidelines highlight the dosimetric value of brachytherapy. This article summarizes the role of LDR-BT in managing prostate cancer and examines patient selection.

### Learning Objectives:

After completing this activity, participants will be able to:

1. Summarize the role of LDR-BT in prostate cancer management.
2. Discuss patient selection for LDR-BT.
3. Understand dosimetric analysis comparison of LDR-BT and external beam.

**Authors:** Ibrahim Abu-Gheida, MD, is a radiation oncology fellow, Christopher Fleming, MD, is a resident, Omar Mian, MD, PhD, is associate staff, Rahul Tendulkar, MD, is the clinical director and residency program director, and Jay Ciezki, MD, is a staff physician, Cleveland Clinic, Taussig Cancer Institute, Department of Radiation Oncology, Cleveland, Ohio. Paul Ramia, MD, is a resident at the American University of Beirut Medical Center, Naef K. Basile Cancer Institute, Department of Radiation Oncology, Beirut, Lebanon.

## OBTAINING CREDITS

**Instructions:** To successfully earn credit, participants must complete the activity during the valid credit period. To receive SA-CME credit, you must:

1. Review this article in its entirety.
2. Visit [www.appliedradiology.org/SAM](http://www.appliedradiology.org/SAM).
3. Login to your account or (new users) create an account.
4. Complete the post test and review the discussion and references.
5. Complete the evaluation.
6. Print your certificate.

**Date of release and review:** September 1, 2017

**Expiration date:** August 31, 2019

**Estimated time for completion:** 1 hour

**Disclosures:** No authors, faculty, or individuals at the Institute for Advanced Medical Education (IAME) or Applied Radiation

Oncology who had control over the content of this program have relationships with commercial supporters.

**Accreditation/Designation Statement:** The IAME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The IAME designates this journal-based activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. These credits qualify as SA-CME credits for ABR diplomates.

**Commercial Support:** None

*As part of this CME activity, the reader should reflect on how it will impact his or her personal practice and discuss its content with colleagues.*